Aridis Pharmaceuticals (Aridis Pharmaceuticals) Short-Term Debt & Capital Lease Obligation : $3.99 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Aridis Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $3.99 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Aridis Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.85 Mil.

Aridis Pharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Aridis Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

Aridis Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.44

0.70

4.84

Aridis Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															9.15	4.84	2.80	5.29	3.99

Aridis Pharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Aridis Pharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Aridis Pharmaceuticals (Aridis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

983 University Avenue, Building B, Los Gatos, CA, USA, 95032

Website

https://www.aridispharma.com

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Executives

Fibrosis Foundation Cystic	10 percent owner	4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri	officer: Chief Medical Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Vu Truong	director, 10 percent owner, officer: CEO, CSO, Director	5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer	director, 10 percent owner	5941 OPTICAL CT., SAN JOSE CA 95138
John F Hamilton	director	1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak	officer: Chief Financial Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland	officer: Chief Financial Officer	C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo	director
Shawn Lu	director	C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin	director	5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025